Safe drugs and the cost of good intentions

New England Journal of Medicine

Volumn 360, Issue 14, 2009, Pages 1378-1380

  Eichler, Hans Georg ^a   Abadie, Eric ^b,c   Raine, June M ^b,d   Salmonson, Tomas ^b,e  

^a EMEA   (United Kingdom)

^b Committee for Medicinal Products for Human Use ^*

^c AFSSAPS   (France)

^d MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTHORITY; DECISION MAKING; DRUG COST; DRUG EFFECT; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SHORT SURVEY; ARTICLE; DRUG APPROVAL; DRUG LEGISLATION; DRUG TOXICITY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; LEGAL ASPECT; METHODOLOGY; RISK ASSESSMENT; STANDARD; UNITED STATES;

DRUG;

DRUG APPROVAL; DRUG INDUSTRY; DRUG TOXICITY; EUROPEAN UNION; GOVERNMENT REGULATION; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 63849288816     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp0900092     Document Type: Article

References (5)

1. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med 2008;5(3):e67.
2. Fischhoff B. Risk perception and communication. In: Detels R, Beaglehole R, Lansang MA, Gulliford M, eds. Oxford textbook of public health. 5th ed. Oxford, England: Oxford University Press (in press).
3. Calfee J. A representative survey of M.S. patients on attitudes towards the benefits and risks of drug therapy. Washington, DC: AEI-Brookings Joint Center for Regulatory Studies, 2006.
4. Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analysis of natalizumab. Neurology 2008;71:357-364
5. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006;185:544-548